GTx, Inc (NASDAQ:GTXI) has unveiled results for its recent trial. It was a study to evaluate enobosarm in post-menopausal women struggling with stress urinary incontinence (SUI).The orally-administered enobosarm didn’t sufficiently separate from the placebo.
The turn of events
GTx, Inc outlines that it conducted the enobosarm treatment over a period of 12 weeks. It discovered that the percentage of patients with greater than 50% reduction were 57.7% for 1mg, 58.9% for 3mg and 52.7% for placebo. The tolerance associated with Enobosarm was remarkable according to the company. The cases of adverse events were minimal and quite similar across the various treatment groups.
The Executive Chairman of GTx Robert J. Wills said, “We are very disappointed that the ASTRID Trial did not achieve its primary endpoint. We plan to conduct a full review of all the data.”
Wills outlined that they had plans underway to carry out a full review of all the data. Besides that, the official thanked the study coordinators, physicians, patients and the entire GTx team. All these parties showed great support in the novel trial.
Focusing into the future
GTx currently seeks to assess the potential of SARDs .It hopes to achieve quite much with its ongoing preclinical program. The business guru says it counts on the selective androgen receptor degrader technology. If all moves according to plan, it might soon succeed on its quest to treat the castration-resistant prostate cancer.
GTx will have development candidates by the time the year comes to a close. The company plans to take them into the IND-enabling studies.
Stress urinary incontinence (SUI) is a serious condition that has caused great discomfort among women over the years. Most of them complain about the unintentional leakages of urine in the course of activities that increase abdominal pressure such as physical exercise, sneezing and coughing.
Reports indicate that SUI affects 35 percent of adult women who on a yearly basis move out to seek out treatment.
They come across a wide range of treatments ranging from the pelvic floor physical therapy to behavioral modification. This are however the initial treatment options.
This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.